trial

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

NCTId NCT00139906
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment —
Sponsored by Solvay Pharmaceuticals
Primary completion 2006-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
—
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2005-08
Primary completion
2006-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

Solvay PharmaceuticalsLead Sponsor
H. Lundbeck A/SCollaborator
Wyeth is now a wholly owned subsidiary of PfizerCollaborator

Investigators

1
Global Clinical Director SolvayStudy Director

Sites

1 total
National City, United States

Linked catalysts

1
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia — primary completion2006-10

Facts & assertions

3 sourced
Phase
PHASE2
Primary Completion Date
2006-10
Status
COMPLETED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
Solvay Pharmaceuticals
company
collaborator
H. Lundbeck A/S
company
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Global Clinical Director Solvay
person